Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.06)
# 2,892
Out of 4,761 analysts
27
Total ratings
43.48%
Success rate
-4.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $7.63 | +201.44% | 1 | Jan 28, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $2.06 | +191.26% | 2 | Dec 20, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $675 → $706 | $644.48 | +9.55% | 4 | Nov 21, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $179 → $170 | $106.28 | +59.95% | 9 | Nov 7, 2024 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $65 | $5.96 | +990.60% | 2 | Aug 26, 2024 | |
| FHTX Foghorn Therapeutics | Initiates: Outperform | $20 | $5.23 | +282.41% | 1 | Aug 19, 2024 | |
| KRYS Krystal Biotech | Maintains: Outperform | $201 → $206 | $187.86 | +9.66% | 1 | Aug 12, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $62 → $66 | $52.45 | +25.83% | 2 | Aug 8, 2024 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $22 | $2.24 | +882.14% | 1 | Oct 3, 2023 | |
| CCCC C4 Therapeutics | Maintains: Outperform | $20 → $10 | $3.01 | +232.23% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $159 → $165 | $202.08 | -18.35% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $12.56 | +377.71% | 1 | Oct 5, 2022 |
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $7.63
Upside: +201.44%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $2.06
Upside: +191.26%
argenx SE
Nov 21, 2024
Maintains: Outperform
Price Target: $675 → $706
Current: $644.48
Upside: +9.55%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $106.28
Upside: +59.95%
Jasper Therapeutics
Aug 26, 2024
Maintains: Outperform
Price Target: $65
Current: $5.96
Upside: +990.60%
Foghorn Therapeutics
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $5.23
Upside: +282.41%
Krystal Biotech
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $187.86
Upside: +9.66%
Mirum Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $62 → $66
Current: $52.45
Upside: +25.83%
Aclaris Therapeutics
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $2.24
Upside: +882.14%
C4 Therapeutics
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $3.01
Upside: +232.23%
Feb 9, 2023
Maintains: Outperform
Price Target: $159 → $165
Current: $202.08
Upside: -18.35%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $12.56
Upside: +377.71%